Treatment of colorectal cancer: Hepatic metastasis

Seminars in Surgical Oncology

Volumn 12, Issue 4, 1996, Pages 219-252

  Fong, Yuman ^a   Kemeny, Nancy ^a   Paty, Philip ^a   Blumgart, Leslie H ^a   Cohen, Alfred M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

chemotherapy; colorectal; hepatic artery chemotherapy; hepatic metastases; surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; FLOXURIDINE; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CRYOSURGERY; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; MORBIDITY; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE;

EID: 0030016950     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8     Document Type: Review

References (215)

1. Weiss L, Grundmann E, Torhorst J, et al.: Haematogenous metastatic patterns in colonie carcinoma: an analysis of 1541 necropsies. J Pathol 150:195-203, 1986.
2. Rosen CB, Nagorney DM, Taswell HF, et al.: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 216:-493-505, 1992.
3. Jaffe BM, Donegan WL, Watson F: Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127:1-11, 1968.
4. Bengmark S, Hafström L: The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma at laparatomy. Cancer 23:198-202, 1969.
5. Goslin R, Steele G, Zamcheck N, et al.: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon and rectum. Dis Colon Rectum 25:749-754, 1982.
6. Bengtsson G, Carlsson G, Hafstrõm L: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141:586-589, 1981.
7. Finan PJ, Marshall RJ, Cooper EH, et al.: Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 72.373-377, 1985.
8. De Brauw LM, De Velde CJH, Bouwhuis-Hoogerwerf ML: Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 34:81-86, 1987.
9. Abrams MS, Lerner HJ. Survival of patients at Pennsylvania Hospital with hepatic metastases from carcinoma of the colon and rectum. Dis Colon Rectum 14:431-434, 1971.
10. Wilson SM, Adson MA: Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 111.330-334, 1976.
11. Wanebo HJ, Semoglou C, Attiyeh F, et al . Surgical management of patients with primary operable colorectal cancer and synchronous liver metastaes. Am J Surg 135.81-84, 1978.
12. Swinton NW, Countz RL: Cancer of the colon and the rectum, statistical study with end results JAMA 161: 139-1143, 1956.
13. Cady B, Monson DO, Swinton NW: Survival of patients after colonic resection for carcinoma with simultaneous liver metastases Surg Gynecol Obstet 131:697-700, 1970
14. Johnson WR, McDermott FT, Pihl E, et al.: Palliative operative management in rectal cancer. Dis Colon Rectum 24:606-612, 1981.
15. Fischerman K, Peterson CF, Christensen KC, et al.: Survival among patients with liver metastases from cancer of the colon and rectum. Scan J Gastroenterol (Suppl) 37:111, 1976.
16. Arnaud JP, Dumont P, Adloff M, et al.: Natural history of colorectal carcinoma with untreated liver metastases. Surg Gastroenterol 3:37-42, 1984.
17. Boey J, Choi TK, Wong J, et al: Carcinoma of the colon and the rectum with liver involvement. Sure Gynecol Obstet 153: 864-868, 1981.
18. Bengmark S, Hafström L, Jeppsson B, et al.: Metasiatic disease in the liver from colorectal cancer an appraisal of liver surgery. World J Surg 6:61-65, 1982.
19. Wagner JS, Adson MA, van Heerden JA, et al.: The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 199:502-508, 1984.
20. Pettavel J, Morgenthaler F: Protracted arterial chemotherapy of liver tumors: an experience of 107 cases over a 12-year period. Prog Clin Cancer 7:217-233, 1978.
21. August DA, Sugarbaker PH, Ottow RT, et al.: Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 201:210-218, 1985.
22. Kemeny N, Braun DW: Prognostic factors in advanced colorectal carcinoma: importance of lactic dehydrogenase level, performance status and white blood cell count. Am J Med 74:786-794, 1983.
23. Kemeny N, Niedzwiecki D, Shurgot B, et al.: Prognostic variables in patients with hepatic metastases from colorectal cancer: importance of medical assessment of liver involvement. Cancer 63:742-747, 1989.
24. Silen W: Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg 124:1021-1024, 1989.
25. Scheele J, Stangl R, Altendor-Hofmann A, et al.: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110:13-29, 1991.
26. Kemeny NM, Sugarbaker PH, Smith TJ, et al.: A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 195:163-167, 1982.
27. Heiken JP. Weyman PJ, Lee JKT, et al.: Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portoaraphy, and MR imaging. Radiology 171:47-51, 1989.
28. Moran B, O'Rourke G, Plant G, et al.: Computed tomographic portography in preoperative imagine of hepatic neoplasms. Br J Surg 82:669-671, 1995.
29. Goldenberg DM, Goldenberg H, Sharkey RM, et al.: Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 19:262-281, 1989.
30. John TG, Greig JD, Crosbie JL, et al: Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 220:711-719, 1994.
31. Heidelberger C, Chaudhuari NK, Danenberg P, et al.: Fluorinated pyrimidines: a new class of tumor inhibitory compounds Nature 179:663-666, 1957.
32. Kufe DW, Major PP: 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256:9802-9805, 1981.
33. Major PP, Egan E, Herrick D, et al., 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res 42:3005-3009, 1982.
34. Finch RE, Bending MR, Lant AF: Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 7:613-617, 1979.
35. MacMillan WE, Wolberg WH, Welling PG: Pharmacokinetics of fluorouracil in humans. Cancer Res 38:3479-3482, 1978.
36. Collins JM, Dedrick RL, King FG, et al.: Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharm Ther 28:235-246, 1980.
37. Wagner JG, Gyves JW, Stetson PL, et al.: Steady-stale non-linear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46:1499-1506, 1986.
38. Mukherjee KL, Boohar J, Wentland D, et al.: Studies on fluorinated pyrimidines: XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 23:49-66, 1963.
39. Clarkson RB, O'Connor A, Winston L, et al.: The physiologic disposition of 5-fluorouracil and 5-fluoro-deoxyuridine in man. Clin Pharmacol Ther 5:581-610, 1964.
40. Carter SK: Large bowel cancer: the current status of treatment. J Nal Cancer Inst 56:3-10, 1976.
41. Ansfield F, Schroeder JM, Curreri AR: Five years experience with 5-fluorouracil. JAMA 181:295, 1962.
42. Lahiri SR, Bioleau G, Hall TC: Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth. Cancer 28: 902-906, 1971.
43. Hahn RG, Moertel CG, Shutt AJ, et al.: A double-blind comparison of intensive course 5-FU by oral vs. intravenous route in the treatment of colon carcinoma. Cancer 35:1031-1036, 1975.
44. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36:675, 1975.
45. Christophidis N, Vajda FJE, Lucas I, et al.: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3:330-336, 1978.
46. Bateman J, Irwin L, Pugh R, et al.: Comparison of intravenous and oral administration of 5-fluorouracil for colorectal carcinoma. Proc Am Assoc Cancer Res 16:242, 1975.
47. Lokich JJ, Ahlgren JD, Gullo JJ, et al.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7:425-432, 1989.
48. Leichman CC, Fleming: Phase II study of fluorouracil and its modulation in advanced colorectal cancer. A Southwest Oncology Group study. J Clin Oncol 13(c):1303-1311, 1995.
49. Martin D: Biochemical modulation: perspectives and objectives. In Harrap K, Connors T (eds): "New Avenues in Developmental Chemotherapy." London: Academic, 1987, 113-162.
50. Rustum Y, Trave F, Zakrzewski S, et al.: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5:165-170, 1987.
51. Advanced Colorectal Cancer Metaanalysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
52. Pazdur R, Ajani JA, Patt YZ, et al.: Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8:2027-2031, 1990.
53. Wadler S, Schwartz EL, Goldman M, et al.: 5-Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal cancer. J Clin Oncol 7:1769-1775, 1989.
54. Wadler S, Wiernik PH: Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 17 (suppl 1):16-21, 1990.
55. Kemeny N, Younes A, Seiter K, et al.: Combination fluorouracil (FU) and recombinant alpha-interferon (Ifn) in advanced colorectal carcinoma: activity but significant toxicity. Cancer 66:2470-2475, 1990.
56. Hill M, Norman: Royal Marsden phase III trial of fluorouracil with or without Interferon alfa-26 in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995.
57. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995.
58. Kemeny NE, Ahmed T, Michaelson RA, et al.: Activity of sequential low dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J Clin Oncol 2:311-315, 1984.
59. Glimelius B, Ginman C, Graffman S, et al.: Sequential methotrexate-5-FU-leucovorin (MFL) in advanced colorectal cancer. Eur J Cancer Clin Oncol 22:295-300, 1986.
60. Benz C, DeGregorio M, Saks S, et al.: Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer pharmacology, toxicitv and response. Cancer Res 45:3354-3358, 1985.
61. Alan M, Coat S, Hedley D, et al.: Randomized trial of sequential methotrexate (M) following 5-fluorouracil (F) versus F followed by M. Proc Am Assoc Cancer Res 24:140, 1983.
62. Cantrell JE, Brunet R, Largarde C: Phase 11 study of sequential methotrexate 5-FU therapy in advanced measurable colorectal cancer. Cancer Treat Rep 66:1563-1565, 1982.
63. Blumenreich MS, Woodcock TM, Allegra M, et al.: Sequential therapy with methotrexate (MTX) and 5-fluorouracil (5-FU) for adenocarcinoma of the colon (abstr). Proc ASCO 1:102, 1982.
64. Panasci L, Ford J, Margolese R: A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. Cancer Chemother Pharmacol 15:164-166, 1985.
65. Burnet R, Smith TKP, Hoemi B, et al.: Sequential methotrexate, 5-fluorouracil in advanced measurable colorectal cancer. Lack of appreciable syneraism. Proc Am Assoc Cancer Res 22:370, 1981.
66. Anjani JA, Kanojia MD, Bedikian AY, et al.: Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncl 8:69-71, 1985.
67. Hansen RM, Quebbeman EJ, Ritch PS, et al.: Continous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. Am J Clin Oncol 10:216-218, 1987.
68. Mackintosh J, Coates A, Swanson C, et al.: Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. Am J Clin Oncol 10:210-212, 1987.
69. Marsh JC, Bertino JR, Katz KH, et al.: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991.
70. Wilmanns W, Possinger K, Schalhom A, et al.: Low dose leucovorin rescue in patients with sequential methotrexate (MTX)/5-fiuorouracil (5-FU) therapy. In "Third European Conference on Clinical Oncology and Cancer Nursing." June 16-20, Stockholm, Sweden, 1985, p 111.
71. Kirkwood JM, Ensminger W, Kosowsky A, et al.: Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent ihymidine infusions in a phase 1 trial. Cancer Res 40:107-113, 1980.
72. Lynch G, Kemeny N, Chun H, et al.: Phase I evaluation and pharmacokinetic study of weekly IV thymidine and 5-FU in patients with advanced colorectal carcinoma. Cancer Treat Rep 69:179-184, 1985.
73. Presant CA, Multhauf P, Klein L: Thymidine and 5-FU: a phase II pilot studying colorectal and breast. Cancer Treat Rep 67:735-736, 1983.
74. Bedikian AY, Stroehlein JR, Karlin DA, et al.: Chemotherapy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat Rep 65:747-753, 1981.
75. Muggia FM, Camacho FJ, Karlin DA, et al.: Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer Cancer Treat Rep 71:253-256, 1987.
76. Martin DS, Stolfi RL, Sawyer RC, et al.: Therapeutic utility of utilizing low dose of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res 43:2317-2321, 1983.
77. O'Dwyer PJ, Paul AR, Walczak J, et al.: Phase 11 study of biochemical modulatin of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497-1503, 1990.
78. Kemeny N, Seiter K, Martin D, et al.: A new syndrome: ascites, hyperbilirubinemia and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspanate (PALA). Ann Intern Med 115:946-951, 1991.
79. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989.
80. Schilsky R: Principles of chemotherapy. In Cohen AM, Winawer SJ (eds): "Cancer of the Colon. Rectum and Anus." New York: McGraw-Hill, Inc., 1995, 893-910.
81. Allegra C, Chu E: Autoregulatory translational control of thymidylate synthase. In: "Proceedings of the 7th NCl-EORTC Symposium on New Drugs in Cancer Therapy." Amsterdam. 1992.
82. Johnston PG, Fisher E, Rockette HE, et al.: Thymidylate synthase expression is an independent predictor of survival/disease-free survival in patients with rectal cancer. Proc Am Soc Clin Oncol 1993.
83. Scheele J: Segment oriented resection of the liver: rationale and technique in hepato-biliary and pancreatic malignancies. In Lygidakis NJ, Tytgat GNJ (eds): Stuttgart: Thieme, 1988.
84. Baer HU, Gertsch P, Matthews JB, et al.: Resectability of large focal liver lesions. Br J Surg 76:1042-1044, 1989.
85. Weinbren HK, Blumgart LH: Pathological changes in the liver and computed tomography. Recent Results Cancer Res 100:58-67, 1986.
86. Adson MA, van Heerden JA, Adson MH: Resection of hepatic metastases from colorectal cancer. Arch Surg 119:647-651, 1984.
87. Fortner JG, Silva JS, Cox EB, et al.: Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. Ann Surg 199:317-323, 1984.
88. Butler J, Attiyeh FF, Daly JM: Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 162:109-113, 1986.
89. Pagana TJ: A new technique for hepatic infusional chemotherapy Semm Surg Oncol 2:99-102, 1986.
90. Hughes KS, Simon R, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 103:278-288, 1988.
91. Adson MA, van Heerden JA, Adson MH, et al.: Resection of hepatic metastases from colorectal cancer: major hepatic resection for metachronous metastases from colon cancer. Arch Surg Ann Surg 201.204-209, 1985.
92. Cobourn CS, Makowka L, Langer B, et al.: Examination of patient selection and outcome for hepatic resection for metastatic disease. Surg Gynecol Obstet 165:239-246, 1987.
93. Schlag P, Hohenberger P, Herfath C: Resection of liver metastases in colorecial cancer - competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 16 360-365, 1990.
94. Doci R, Gennari L, Bignami P, et al.: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of proenostic determinants. Br J Surg 78: 797-801, 1991
95. Younes RN, Rogatko A, Brennan MF. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 214:107-113, 1991.
96. Coppa GF, Eng K, Ranson JCH, et al.: Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg 302:203-208, 1985.
97. Cunningham JD, Fong Y, Shriver C, et al.: One hundred consecutive hepatic resections: blood loss, transfusion and operative technique. Arch Surg 1994.
98. Hughes KS, Rosenstein RB, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum 31:1-4, 1988.
99. Moertel CG, Reitemeyer RJ: "Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy." New York: Harper & Row. 1969.
100. Morrow CE, Grage TB, Sutherland DER, et al.: Hepatic resection for secondary neoplasms. Surgery 92:610-614, 1982.
101. Logan SE, Meier SJ, Ramming KP, et al.: Hepatic resection of metastatic colorectal carcinoma. Arch Surg 117:25-28, 1982.
102. Iwatsuki S, Esquivel CO, Gordon RD, et al.: Liver resection for metastatic colorectal cancer. Surgery 100:804-810, 1986.
103. Wang XD, Anderson R, Soltesz V, et al.: Bacterial translocation after major hepatectomy in patients and rats. Arch Surg 127:1101-1106, 1992.
104. Vogt P, Raab R, Ringe B, et al.: Resection of synchronous liver metastases from colorectal cancer. World J Surg 15:62-67, 1991.
105. Nakamura S, Yokoi Y, Suzuki S, et al.: Results of extensive surgery for Siver metastases in colorectal carcinoma. Br J Surg 79:35-38, 1992.
106. Hughes KS, Simon R, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100:278-284, 1986.
107. Eckberg H, Tranberg KG, Andersson R, et al.: Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11:541-547, 1987.
108. Hill DL, Grubbs CJ: Retinoids and cancer prevention. Annu Rev Nutr 12:161-181, 1992.
109. Cady B, Stone MD, McDermott WV, Jr, et al.: Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 127:561-569, 1992.
110. Stephenson KR, Steinberg SM, Hughes KS, et al.: Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastasis. Ann Surg 208:679-687, 1988.
111. Cady B, McDermott WV: Major hepatic resection for metachronous metastases from colon cancer. Ann Surg 201:204-209, 1985.
112. McCormack P, Martini N: Secondary tumors in the lung. In Shields TW (ed). "General Thoracic Surgery" (3rd ed). Philadelphia: Lea & Febiger, 1989, 951-959.
113. Smith JW, Fortner JG, Burt M: Resection of hepatic and pulmonary metastases from colorectal cancer. Surg Oncol 1:399-404, 1992.
114. Weinbren K, Adam A, Blumgart LH, et al.: Apparent extrahepatic invasion by metastauc tumors in the liver. Clin Radiol 38:357-362, 1987.
115. Bozzetti F, Bignami P, Morabito A, et al.: Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg 205:264-270, 1987.
116. Maeda T, Hasebe Y, Hanawa S, et al.: Trial of percutaneous hepatic cryo therapy, preliminary report [Japanese]. Nippon Geka Gakkai Zasshi 93:666, 1992.
117. Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg 220:50-52, 1994.
118. Hohenberger P, Schlag P, Schwarz V, et al.: Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol 44:245-251, 1990.
119. Kemeny N, Daly J, Reichman B, et al.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma - a randomized trial. Ann Intern Med 107:459-465, 1987.
120. Chang AE, Schneider PD, Sugarbaker PH. et al.: A prospective randomized trial of regional vs systemic continuous 5-FU chemotherapy in the treatment of colorectal metastases Ann Surg 206:685-693, 1987.
121. Grossman S, Milos ML, Tekawa IS, et al.: Colonoscopic screening of persons with suspected risk factors for colon cancer: II. Past history of colorectal neoplasms. Gastroenterology 96:299-306, 1989.
122. Wagman LD, Kemeny MM, Leong L, et al.: A prospective, randomized evaluation of the treatment of colorectal cancer metastalic to the liver. J Clin Oncol 8:1885-1893, 1990
123. Martin JK, O'Connell MJ, Wieand HS, et al.: Intra-arterial floxuridine vs systemic fiuorouracil for hepatic metastases from colorectal cancer. Arch Surg 125:1022-1027, 1990.
124. Rougier P, Laplanche A, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10:1112-1118, 1992.
125. Patt, YZ: Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. J Clin Oncol 11:815-819, 1993.
126. Goodie DB, Horton MD, Morris RW, et al.: Anaesthetic experience with cryotherapy for treatment of hepatic malignancy. Anaesth Intensive Care 20:491-496, 1992.
127. Moriya Y, Sugihara K, Hojo K, et al.: Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study. Eur J Surg Oncol 17:519-525, 1991.
128. Curley SA, Roh MS, Chase JL, et al.: Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg 166:743-748, 1993.
129. Kemeny MM, Goldberg D, Beatty JD, et al.: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepataic metastases from colorectal primaries. Cancer 57:492-498, 1986.
130. Fortner JG: Recurrence of colorectal cancer after hepatic resection. Am J Surg 155:378-382, 1988.
131. Bozetti F, Bignami P, Montalto F, et al.: Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg 79:146-148, 1992.
132. Griffith KD, Sugarbaker PH, Chang AE: Repeat hepatic resections for colorectal metastases. Br J Surg 77:230-233, 1990.
133. Lange JF, Leese T, Castaing D, et al.: Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet 169:119-126, 1989.
134. Fong Y, Blumgart LH, Cohen A, et al.: Repeat hepatic resection for metastatic colorectal cancer. Ann Surg 1994.
135. Wagner JS, Adson MA, van Heerden JA, et al.: The natural history of hepatic metastases from colorectal cancer. Arch Surg 111:330-334, 1976.
136. Hass GM, Taylor CB: Quantitative hypothermal method for production of local injurv of tissue. Arch Pathol 45:563-580, 1948.
137. Bayjoo P, Jacob G: Hepatic cryosurgery: biological and clinical considerations. J R Coll Sure Edinb 37:369-372, 1992.
138. Schlinkert RT, Chapman TP: Nitrogen embolus as a complication of hepatic cryosurgery. Arch Surg 125:1214, 1990
139. Charnley RM, Doran J, Morris DL: Cryotherapy for liver metastases: a new approach [see comments]. Br J Surg 76:1040-1041, 1989.
140. Morris DL, Horton MD, Dilley AV, et al.: Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion. Gut 34:1158-1161, 1993.
141. Ravikumar TS, Steele G, Jr, Kane R, et al.: Experimental and clinical observations on hepatic cryosurgery for colorectal metastases. Cancer Res 51:6323-6327, 1991.
142. Ravikumar TS, Kane R, Cady B, et al.: A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 126:1520-1524, 1991.
143. Steele G, Jr, Ravikumar TS, Benotti PN: New surgical treatments for recurrent colorectal cancer [review]. Cancer 65:723-730, 1990.
144. Onik G, Rubinsky B, Zemel R, et al.: Ultrasound-guided hepatic cryosurgerv in the treatment of metastatic colon carcinoma - preliminary results. Cancer 67:901-906, 1991.
145. Taylor I: Cytotoxic perfusion for colorectal liver metastases. Br J Surg 65:109-114, 1978.
146. Ramming KP, Sparks FC, Eilber FR, et al.: Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg 132:236-242, 1976.
147. Berjian RA, Douglas HO, Nava HR, et al.: The role of hepatic artery ligation and dearterialization with infusion chemotherapy in advanced malignancies in the liver. J Surg Oncol 14:379-387, 1980.
148. Petrelli NJ, Barcewicz PA, Evans JT, et al.: Hepatic artery ligation for liver metastasis in colorectal carcinoma. Cancer 53:1347-1353, 1984.
149. Persson B, Jeppson B, Ekelund L, et al.: A new device for temporary occlusion of the hepatic artery. J Surg Res 3:155-160, 1984.
150. Bengmark S, Jeppson B, Nobin A: Arterial ligation and temporary dearterialization. In Blumgart LH (ed): "Surgery of the Liver and Biliary Tract." London: Churchill Livingstone, 1988, 1219-1236.
151. El-Domeiri AA, Mojab K: Intermittent occlusion of the hepatic artery and infusion chemotherapy for carcinoma of the liver. Am J Surg 135:771-776, 1978.
152. Breedis C, Young C: The blood supply of neoplasms in the liver. Am J Pathol 30:969, 1954.
153. Ensminger WD, Rosowsky A, Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978.
154. Ensminger WD, Gyves JW: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10:176-183, 1983.
155. Ansfield FJ, Ramirez G, Davis HL, Jr, et al.: Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer 36:2413-2417, 1975.
156. Niederhuber JE, Ensminger W, Gyves J, et al.: Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53:1336-1343, 1984.
157. Hohn DC, Stagg RJ, Friedman MA, et al.: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646-1654, 1989.
158. Kemeny N, Seiter K, Niedzwiecki D, et al.: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 11:330-335, 1993.
159. Kemeny N, Seiter K, Conti J, et al.: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma: new dose schedules and survival update. Cancer 73:1134-1142, 1994.
160. Kemeny N, Seiter K, Niedzwiecki D, et al.: A randomized trial of intrahepatic infusion of fluorodeoxy uridine with dexamethasone versus fluorodeoxy undine alone in the treatment of metastatic colorectal cancer. Cancer 69:327-334, 1992.
161. Kemeny N, Conti JA, Cohen A, et al.: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12.2288-2295, 1994.
162. Hohn DC, Stagg RJ, Price DC, et al.: Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2-deoxyuridine. J Clin Oncol 3:1257-1260, 1985.
163. Doria MI, Shepard KV, Levin B, et al.: Liver pathology following hepatic arterial infusion chemotherapy. Cancer 58: 855-861, 1986.
164. Creech O, Jr. Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616-632, 1958.
165. Ku Y, Saitoh M, Nishiyama H, et al.: Extracorporeal removal of anticancer drugs in hepatic artery infusion: the effect of hemoperfusion combined with veno-venous bypass. Surgery 107:273-281, 1990.
166. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992.
167. Bismuth H: Surgical anatomy and anatomic surgery of the liver. World J Surg 6:3-9, 1982.
168. Blumgart LH: Liver resection - liver and biliary tumours. In Blumgart LH (ed): "Surgery of the Liver and Biliary Tract" (2nd ed). London: Churchill Livingstone, 1994, 1495-1538.
169. Couinaud C: Bases anatomiques des hepatectomies gauche et droite reglees. J Chir (Paris) 70:933-966, 1957.
170. Couinaud C: Etudes anatomiques et chirurgicales. Mason 400-409, 1957.
171. Glisson F: "Anatomia Hepatis." London: O Pullein, 1654.
172. Smadja C, Blumgart LH: The biliary tract and the anatomy of biliary exposure. In Blumgart LH (ed): "Surgery of the Liver and Biliary Tract" (2nd ed). London: Churchill Livingstone, 1994, 11-24.
173. Launois B, Jamieson GG: The importance of Glisson's capsule and its sheaths in the intrahepatic approach to resection of the liver. Surg Gynecol Obstet 174:7-10, 1992.
174. Goldsmith NA, Woodburne RT: The surgical anatomy pertainina to liver resection. Surg Gvnecol Obstet 105:310-318, 1957.
175. Castaing D, Kunstlinger F, Habib N: Intraoperative ultrasound study of the liver: methodology and anatomical results. Am J Surg 149:676-682, 1985.
176. Fong Y, Brennan M, Brown K, et al.: Drainage is unnecessary after elective liver resection: results of a randomized trial. Am J Surg 1995.
177. Czerniak A, Shabtai M, Avigad I, et al.: A direct approach to the left and middle hepatic veins during left-sided hepatectomy. Surg Gynecol Obstet 1992.
178. Starzl TE. Iwatsuki S, Shaw BW, et al.: Left hepatic trisegmentectomy. Surg Gynecol Obstet 155:21-27, 1982.
179. Blumgart LH, Baer HU, Czerniak A. et al.: Extended left hepatectomy: technical aspects of an evolving procedure. Br J Surg 80:903-906, 1993.
180. Soreide O, Czerniak A, Blumgart LH: Large hepatocellular cancers: resection of liver transplant. Br Med J 291:853-857, 1985.
181. Baer HU, Dennison AR, Maddern GJ: Subtotal hepatectomy: a new procedure based on the inferior right hepatic vein. Br J Surg 78:1221-1222, 1991.
182. Scheele J, Stangl R: Segment oriented anatomical liver resections In Blumgart LH (edt: "Surgery of the Liver and Biliary Tract" (2nd ed). London. Churchill Livingstone, 1994, 1557-1578.
183. Lerut J, Gruwez J, Blumgart LH: Resection of the caudate lobe of the liver. Surg Gynecol Obstet 171:160-162, 1990.
184. Elias D, Lasser P, Descruennes E, et al.: Surgical approach to seement I for malignant tumors of the liver Surg Gynecol Obstet 175:17-24, 1992.
185. Babineau TJ, Lewis WD, Jenkins RL, et al.: Role of staging laparoscopy in the treatment of hepatic malignancy. Am J Sure 167:151-155, 1994.
186. Polk W, Fong Y, Karpeh M, et al.: A technique for the use of cryosurgery to assist hepatectomy. J Am Coll Surg 180: 171-176, 1995.
187. Cohen AM, Higgins J, Waltman AC, et al.: Effect of ligation of variant hepatic arterial structures on the completeness of regional chemotherapy infusion. Am J Surg 153:378-380, 1987.
188. Nielsen J, Barlslev I, Jensen HE: Carcinoma of the colon with liver metastases. Acta Chir Scand 137:463-465, 1971.
189. Wood CB, Gillis CR, Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2:285-288, 1976.
190. Petrelli N, Herrera L, Rustum Y, et al.: A prospective randomized trial of 5-ffuorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987.
191. Valone FH, Friedman MA, Wittlinger PS, et al.: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989.
192. Ehrlichman C, Fine S, Wong A, et al.: Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988.
193. Petrelli N, Douglass HO, Jr, Herrera L, et al.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989.
194. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63:1026-1030, 1989.
195. Doroshaw JH, Multhauf P, Leong L, et al.: Prospective randomized comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990.
196. Nobile M, Canobbio L, Sobrero A, et al.: A randomized trial of 5-fluorouracil and high-dose leucovorin in untreated advanced colorectal cancer patients. Adv Exp Med Biol 244: 213-218, 1988.
197. Labianca R, Pancera G, Aitini E, et al.: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer: phase III study of GISCAD (Italian Group for Study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991
198. DiContanzo F, Bartolucci: Fluorouracil alone vs. high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 3:371-376, 1992.
199. Stemke B. Gunther: Fluorouracil versus folinic acid fluorouracil in advanced colorectal cancer - preliminary results of a randomized trial. Semin Oncol 19(suppl 3): 141-147, 1992.
200. Martoni A, Cricca: Weekly regimen of 5-FU vs. 5-FU and intermediate-dose folinic acid in the treatment of advanced colorectal cancer. Anticancer Res 12:607-612, 1992.
201. Bobbio-Pallavicini E, Porta: Folimc acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 5:52-55, 1993.
202. Leichman CG, Fleming: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995.
203. Foster JH: Survival after liver resection for secondary tumors Am J Surg 135:389-394, 1978.
204. Thompson HH, Tompkins RK, Longmire WP, Jr: Major hepatic resection: a 25-year experience. Ann Surg 197:375-388, 1983.
205. Fortner JG, Silva JS, Cox EB, et al.: Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann Surg 199:306-316, 1984.
206. Nordlinger B, Parc R, Delva E, et al.: Hepatic resection for colorectal liver metastases. Ann Surg 205:256-263, 1987.
207. Vaillant JC, Balladur P, Nordlinger B, et al.: Repeat liver resection for recurrent colorectal metastases. Br J Surg 80: 340-344, 1993.
208. Bozetti F, Bignami P, Montalto F, et al.: Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg 79:146-148, 1992.
209. Elias D, Lasser P, Hoang JM, et al.: Repeat hepatectomy for cancer. Br J Surg 80:1557-1562, 1993.
210. Stone MD, Cady B, Jenkins RL, et al.: Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 125:718-721, 1990.
211. Que FG, Nagorney DM: Resection of "recurrent" colorectal metastases to the liver. Br J Surg 81:255-258, 1994.
212. Rougier P, Hay JM, Olivier JM, et al.: A controlled muhicentric trial of intrahepatic artery chemotherapy vs. standard palliative treatment for colorectal liver metastases. Proc Am Soc Clin Oncol 9:104, 1990.
213. Daly JM, Kemeny N, Oderman P, et al.: Long-term hepatic arterial infusion. Arch Surg 119:936-941, 1984.
214. Hohn DC, Rayner AA, Economou JS, et al.: Toxicities and complications of implanted pump hepatic arterial and intravenous floxundine infusion. Cancer 57:465-470, 1986.
215. Michels NA: Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg 112:337-347, 1962.